- Home
- IMMX vs RPTX Comparison
IMMX vs RPTX Comparison
Compare IMMX & RPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMX
- RPTX
- Stock Information
- Founded
- IMMX 2014
- RPTX 2016
- Country
- IMMX United States
- RPTX Canada
- Employees
- IMMX N/A
- RPTX N/A
- Industry
- IMMX Medicinal Chemicals and Botanical Products
- RPTX Biotechnology: Pharmaceutical Preparations
- Sector
- IMMX Health Care
- RPTX Health Care
- Exchange
- IMMX Nasdaq
- RPTX Nasdaq
- Market Cap
- IMMX 55.3M
- RPTX 54.0M
- IPO Year
- IMMX 2021
- RPTX 2020
- Fundamental
- Price
- IMMX $1.76
- RPTX $1.29
- Analyst Decision
- IMMX Strong Buy
- RPTX Strong Buy
- Analyst Count
- IMMX 1
- RPTX 3
- Target Price
- IMMX $7.00
- RPTX $7.00
- AVG Volume (30 Days)
- IMMX 83.5K
- RPTX 232.9K
- Earning Date
- IMMX 03-28-2025
- RPTX 03-03-2025
- Dividend Yield
- IMMX N/A
- RPTX N/A
- EPS Growth
- IMMX N/A
- RPTX N/A
- EPS
- IMMX N/A
- RPTX N/A
- Revenue
- IMMX N/A
- RPTX $66,524,000.00
- Revenue This Year
- IMMX N/A
- RPTX $12.15
- Revenue Next Year
- IMMX $600.00
- RPTX N/A
- P/E Ratio
- IMMX N/A
- RPTX N/A
- Revenue Growth
- IMMX N/A
- RPTX 18.19
- 52 Week Low
- IMMX $1.26
- RPTX $1.10
- 52 Week High
- IMMX $3.80
- RPTX $7.45
- Technical
- Relative Strength Index (RSI)
- IMMX 31.71
- RPTX 47.52
- Support Level
- IMMX $1.85
- RPTX $1.13
- Resistance Level
- IMMX $2.14
- RPTX $1.37
- Average True Range (ATR)
- IMMX 0.12
- RPTX 0.09
- MACD
- IMMX -0.02
- RPTX 0.04
- Stochastic Oscillator
- IMMX 8.43
- RPTX 57.14
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
About RPTX Repare Therapeutics Inc.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company derives maximum revenue from Canada.